Policymakers are discussing a misguided drug pricing plan—known as the “Most Favored Nation” policy—that would tie the cost of medicines in the U.S. to prices set by foreign governments. It sounds like a quick fix, but it actually won’t lower out-of-pocket costs for patients—and it comes with serious risks.

The policy would:

• Fail to help patients, with no guarantee of lower costs or better access.
• Let foreign governments dictate U.S. drug prices, weakening our economy and increasing our dependence on China and other countries for new treatments.
• Jeopardize future cures by siphoning billions in R&D—money that could go toward medical breakthroughs and U.S. manufacturing.
• Ignore the real cost drivers—middlemen like PBMs and 340B hospital markups that inflate drug prices and foreign countries that don’t pay their fair share to support global R&D.

Instead of importing foreign price controls, policymakers should focus on real solutions that help patients now—like reining in PBMs, holding 340B hospitals accountable and ending foreign free-riding. Other countries should support the innovation they benefit from and if PBMs and hospitals get lower prices, those savings should go to patients–not profit margins.

Take Action Now

Tell your Senator: Reject the Most Favored Nation policy. Say no to foreign reference pricing that harms patients and threatens biopharmaceutical innovation. Instead, support real solutions that put Americans first.